The C-terminal segment of Leishmania major HslU: Toward potential inhibitors of LmHslVU activity.

[Display omitted] • The HslVU protease of Trypanosomatids is a potential drug target. • We developed LmHslU C-terminal-derived peptides binding to LmHslV and potentially inhibiting HslVU assembly. • A SAR study of the C-terminal LmHslU dodecapeptide identified a potent hexapeptide. • Conjugated to a penetrating peptide, it was found to be toxic to parasites in culture. • The fluorescently-labelled conjugate entered the promastigote form of L. infantum. It is urgent to develop less toxic and more efficient treatments for leishmaniases and trypanosomiases. We explore the possibility to target the parasite mitochondrial HslVU protease, which is essential for growth and has no analogue in the human host. For this, we develop compounds potentially inhibiting the complex assembly by mimicking the C-terminal (C-ter) segment of the ATPase HslU. We previously showed that a dodecapeptide derived from Leishmania major HslU C-ter segment (LmC12-U2, Cpd 1) was able to bind to and activate the digestion of a fluorogenic substrate by LmHslV. Here, we present the study of its structure-activity relationships. By replacing each essential residue with related non-proteinogenic residues, we obtained more potent analogues. In particular, a cyclohexylglycine residue at position 11 (cpd 24) allowed a more than three-fold gain in potency while reducing the size of compound 24 from twelve to six residues (cpd 50) without significant loss of potency, opening the way toward short HslU C-ter peptidomimetics as potential inhibitors of HslV proteolytic function. Finally, conjugates constituted of LmC6-U2 analogues and a mitochondrial penetrating peptide were found to penetrate into the promastigote form of L. infantum and to inhibit the parasite growth without showing toxicity toward human THP-1 cells at the same concentration (i.e. 30 μM). [ABSTRACT FROM AUTHOR]